[go: up one dir, main page]

MX2018002998A - Derivado de acido nucleico que tiene actividad inmunoestimuladora. - Google Patents

Derivado de acido nucleico que tiene actividad inmunoestimuladora.

Info

Publication number
MX2018002998A
MX2018002998A MX2018002998A MX2018002998A MX2018002998A MX 2018002998 A MX2018002998 A MX 2018002998A MX 2018002998 A MX2018002998 A MX 2018002998A MX 2018002998 A MX2018002998 A MX 2018002998A MX 2018002998 A MX2018002998 A MX 2018002998A
Authority
MX
Mexico
Prior art keywords
nucleic acid
derived
oligonucleotide
immunostimulating activity
linker
Prior art date
Application number
MX2018002998A
Other languages
English (en)
Other versions
MX374553B (es
Inventor
Kugimiya Akira
Tanino Tetsuya
Sekiguchi Mitsuaki
MITSUOKA Yasunori
Kuroda Norikazu
Nakamura Jun
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2018002998A publication Critical patent/MX2018002998A/es
Publication of MX374553B publication Critical patent/MX374553B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

El propósito de la presente invención es proporcionar un oligonucleótido de doble cadena que comprende el oligonucleótido de CpG mencionado posteriormente, como un derivado de ácido nucleico que tiene una actividad inmunoestimuladora. Un adyuvante que comprende un oligonucleótido de doble cadena, en donde una primera cadena es un oligonucleótido de CpG que está compuesto de 8 a 50 nucleótidos, una segunda cadena es un oligonucleótido que está compuesto de 8 a 60 nucleótidos y que contiene una secuencia capaz de hibridarse con la primera cadena, y un lípido que se une a la segunda cadena a través de un enlazador o sin un enlazador.
MX2018002998A 2015-09-30 2016-09-29 Derivado de ácido nucleico que tiene actividad inmunoestimuladora. MX374553B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015192565 2015-09-30
PCT/JP2016/078765 WO2017057540A1 (ja) 2015-09-30 2016-09-29 免疫賦活活性を有する核酸誘導体

Publications (2)

Publication Number Publication Date
MX2018002998A true MX2018002998A (es) 2018-04-11
MX374553B MX374553B (es) 2025-03-06

Family

ID=58423651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002998A MX374553B (es) 2015-09-30 2016-09-29 Derivado de ácido nucleico que tiene actividad inmunoestimuladora.

Country Status (9)

Country Link
EP (1) EP3357507A4 (es)
JP (1) JP6583864B2 (es)
KR (1) KR102230325B1 (es)
CN (1) CN108472358B (es)
AU (1) AU2016332266B2 (es)
CA (1) CA3000617C (es)
MX (1) MX374553B (es)
RU (1) RU2730871C1 (es)
WO (1) WO2017057540A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7190794B2 (ja) * 2017-03-29 2022-12-16 塩野義製薬株式会社 核酸医薬及び多分岐脂質の複合体
CN108728444A (zh) * 2017-04-18 2018-11-02 长春华普生物技术股份有限公司 免疫调节性多核苷酸及其应用
JP7229539B2 (ja) * 2017-12-27 2023-02-28 神戸天然物化学株式会社 高脂溶性ホスホラミダイトの製造
KR102062291B1 (ko) * 2018-04-23 2020-01-03 주식회사 엔지켐생명과학 글리세롤 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 면역조절제
US12351804B2 (en) 2019-06-03 2025-07-08 Shionogi & Co., Ltd. Production method for bifurcated lipid-linked oligonucleotide, and intermediate
BR112022018361A2 (pt) 2020-03-27 2022-11-08 The Univ Of Kitakyushu Indutor imune contendo conjugado polinucleotídeo-peptídeo e composição farmacêutica contendo o mesmo
EP4444357B1 (en) * 2022-12-19 2025-05-21 Arnatar Therapeutics, Inc Arnatar compounds and methods for enhanced cellular uptake
WO2024259134A1 (en) 2023-06-13 2024-12-19 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar) for angiotensinogen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1200580T3 (da) * 1999-08-13 2005-04-11 Hybridon Inc Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
CA2474709A1 (en) * 2002-02-04 2003-08-14 Biomira, Inc. Immunostimulatory, covalently lipidated oligonucleotides
RU2338750C2 (ru) * 2002-08-19 2008-11-20 Коли Фармасьютикал Груп, Инк. ИММУНОСТИМУЛИРУЮЩИЕ ФОСФОРТИОАТНЫЕ CpG-ОЛИГОНУКЛЕОТИДЫ, СОДЕРЖАЩИЕ ФОСФОДИЭФИРНЫЕ СВЯЗИ, СПОСОБ ИММУНОМОДУЛЯЦИИ, СПОСОБ СТИМУЛИРОВАНИЯ ИММУННОГО ОТВЕТА
AU2005313883B2 (en) * 2004-12-09 2011-03-31 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
BRPI0916884A2 (pt) * 2008-08-28 2016-06-14 Glaxosmithkline Biolog Sa composição imunogênica, processo para preparar uma composição imunogênica, uso de uma composição imunogênica, e, kit
PL2355851T3 (pl) * 2008-11-10 2018-08-31 Arbutus Biopharma Corporation Nowe lipidy i kompozycje do dostarczania środków terapeutycznych
WO2010057150A1 (en) * 2008-11-17 2010-05-20 Enzon Pharmaceuticals, Inc. Releasable polymeric lipids for nucleic acids delivery systems
BRPI0923341B8 (pt) * 2008-12-09 2021-05-25 Coley Pharm Group Inc oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso
KR101634058B1 (ko) * 2008-12-09 2016-06-27 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
US9107904B2 (en) 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
CA2940893C (en) * 2013-03-06 2022-07-26 Marina Vaneva IVANOVA Cpg oligonucleotide formulations and methods and uses thereof
WO2015105083A1 (ja) * 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド

Also Published As

Publication number Publication date
KR102230325B1 (ko) 2021-03-19
EP3357507A4 (en) 2019-05-29
CA3000617C (en) 2021-03-09
RU2730871C1 (ru) 2020-08-26
JP6583864B2 (ja) 2019-10-09
CA3000617A1 (en) 2017-04-06
AU2016332266A1 (en) 2018-03-22
AU2016332266B2 (en) 2020-05-07
MX374553B (es) 2025-03-06
CN108472358A (zh) 2018-08-31
JPWO2017057540A1 (ja) 2018-06-21
EP3357507A1 (en) 2018-08-08
CN108472358B (zh) 2022-06-24
WO2017057540A1 (ja) 2017-04-06
KR20180054854A (ko) 2018-05-24

Similar Documents

Publication Publication Date Title
MX2018002998A (es) Derivado de acido nucleico que tiene actividad inmunoestimuladora.
CY1123289T1 (el) Ενωσεις ολιγονουκλεοτιδιων για τη στοχευση του huntingtin mrna
AR132094A2 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
CY1125385T1 (el) Συστημα πολλαπλων φορεων και χρησεις αυτου
MX2016016526A (es) Acidos nucleicos antisentido.
CO2017007335A2 (es) Supresión del gen de la huntingtina inducida por la arni
MX2024008022A (es) Composiciones y kits para el tratamiento de la hemofilia a o b.
MX386418B (es) Composicion acida que comprende una ficocianina.
MX368723B (es) Composiciones y metodos para inhibir la expresion del gen alas1.
MX2016016905A (es) Ensamblaje de adn mediado por nucleasa.
EA201300585A1 (ru) Иммуномодулирующие олигонуклеотиды
AR100946A1 (es) Composiciones y métodos para regular la expresión génica por medio de la interferencia de arn
DOP2022000085A (es) Composiciones y métodos para inhibir la expresión del gen alas1
MX2016010717A (es) Métodos y composiciones para el perfilado de adn.
MX383931B (es) Compuestos de aza-piridona y usos de estos.
MX2021010716A (es) Composiciones y metodos para inhibir la expresion del gen lect2.
BR112017006680A2 (pt) variantes de vírus influenza a
MX387275B (es) Neoepítopos virales y sus usos
BR112016030604B8 (pt) Processo para preparação de ácidos 3- hidroxipicolínicos
PH12019502063A1 (en) Nucleic acid derivative having immunostimulatory activity
IN2015DN02699A (es)
MX2015013036A (es) Composiciones promotoras.
AR121847A2 (es) Compuestos y composiciones para modular la expresión de tau
BR112018004636A2 (pt) método para modificação de um sítio alvejado em um dna de fita dupla de uma bactéria gram-positiva, complexo de enzima modificadora de ácido nucleico, e, ácido nucleico
BR112018007622A2 (pt) ferramenta genética de transformação de bactérias clostridium

Legal Events

Date Code Title Description
FG Grant or registration